Abstract: Described herein are proteins having lyase activity and nucleic acid sequences which code therefor; along with methods of expressing, isolating, purifying, and using same.

Abstract: Polypeptides having alkanoyl-CoA activity have been identified and characterized, as have nucleic acids encoding these polypeptides. Expression or over-expression of the nucleic acids alters levels of cannabinoid compounds in organisms. The polypeptides may be used in vivo or in vitro to produce cannabinoid compounds.

Abstract: Provided are: a method for stabilizing an ascorbic acid oxidase; a method for preserving an ascorbic acid oxidase; and a stabilized composition of an ascorbic acid oxidase. A method for stabilizing an ascorbic acid oxidase and a method for preserving an ascorbic acid oxidase, each of the methods comprising allowing an ascorbic acid oxidase to coexist with nitrous acid or a salt thereof, or a nitrous acid ester in an aqueous medium; and a stabilized composition of an ascorbic acid oxidase, which comprises an ascorbic acid oxidase being allowed to coexist with nitrous acid or a salt thereof, or a nitrous acid ester in an aqueous medium. The method for stabilizing an ascorbic acid oxidase, the method for preserving an ascorbic acid oxidase, and the stabilized composition of an ascorbic acid oxidase according to the present invention are useful for clinical diagnosis and the like.

Abstract: Provided herein are compositions for the modification of gene expression by RNA interference using a microRNA (miRNA) guide strand precursor. Methods of making and using the miRNA guide strand precursor also are provided. The compositions bypass the Drosha-Exportin-Dicer pathway and are resistant to nucleases.

Abstract: A novel network of tumorigenic prognostic factors is identified that plays a critical role in advanced pancreatic cancer (PC) pathogenesis. This interactome is interconnected through a central tumor suppressive microRNA, miR-198, which is able to both directly and indirectly modulate expression of the various members of this network to alter the molecular makeup of pancreatic tumors, with important clinical implications. When this tumor signature network is intact, miR-198 expression is reduced and patient survival is dismal; patients with higher miR-198 present an altered tumor signature network, better prognosis and increased survival. Further, according to the present disclosure, MiR-198 replacement reverses tumorigenicity in vitro and in vivo.

Abstract: The present disclosure relates generally to cancer and particularly to breast cancer including estrogen sensitive, estrogen resistant and triple negative breast cancer (TNBC), and to methods of diagnosis and prognosis thereof and therapeutic intervention involving replication factor C 40 (RFC40). Methods and assays for evaluating breast cancer are provided. The disclosure also relates to inhibition or modulation of RFC40 in treatment or alleviation of cancer, including breast cancer. RFC40 inhibitors, including siRNAs, miRNAs, and shRNAs, which specifically affect cancer cells, particularly breast cancer cells, are provided.

Abstract: Disclosed are methods and compositions for siRNA-mediated therapy of mammalian diseases. In particular, compositions and methods are disclosed for treatment of therapy-resistant human breast cancers. In exemplary embodiments, siRNA molecules are presented that effectively knock down gene expression of one or more polynucleotides in breast cancer tumor initiating cells.

Abstract: The present embodiments provide compounds and methods for reducing expression of Metastasis-Associated-in-Lung-Adenocarcinoma-Transcript-1 (MALAT-1) RNA and/or protein in an animal. Such methods are useful for treating cancer, such as colon cancer, intestinal cancer, lung cancer (e.g. non-small cell lung cancer), liver cancer, and/or prostate cancer. In various aspects, the cancer is a primary cancer.

Abstract: Some aspects of this invention provide nucleic acid constructs for transgene expression. Some aspects of this invention provide multicistronic nucleic acid constructs, for example, comprising an expression cassette encoding a hairpin RNA and a reporter expression cassette. Some aspects of this invention provide nucleic acid constructs comprising two or more self-complementary nucleic acid sequences, for example, hairpin RNA encoding nucleic acid sequences and AAV inverse terminal repeats. Methods for the use of the constructs in therapy and research are also provided.

Abstract: The present invention provides methods for tumor treatment by administering an inhibitor of quiescin sulfhydryl oxidase 1 (QSOX1), compositions comprising such inhibitors, and methods for identifying such inhibitors.

Abstract: The present invention concerns a chimeric polypeptide comprising several polypeptide domains, which is capable of being secreted in association with membrane vesicles and in particular exosomes. The present invention also concerns a polypeptide constituted by one of said domains for the secretion of a peptide or polypeptide of interest in association with membrane vesicles and in particular exosomes. The invention also concerns the use of polypeptides of the invention and of polynucleotides coding for said polypeptides for the production of immunogenic compositions based on exosomes or based on DNA or for screening protein interactions.

Abstract: The present application provides novel regulatory elements including promoter sequences from marine microorganisms. The application further discloses DNA constructs containing these novel regulatory elements; transgenic cells, transgenic non-human organisms, and progeny containing these novel regulatory elements. Methods of modifying, producing, and using the regulatory elements are also disclosed. The regulatory elements disclosed herein are particularly suited for use in Nannochloropsis and other microalgae.

Abstract: The present invention relates to a plant, which is resistant to a pathogen of viral, bacterial, fungal or oomycete origin, wherein the plant has a reduced level, reduced activity or complete absence of DMR6 protein as compared to a plant that is not resistant to the said pathogen, in particular organisms of the Fungi or the phylum Oomycota. The invention further relates to a method for obtaining a plant, which is resistant to a pathogen of viral, bacterial, fungal or oomycete origin, comprising reducing the endogenous level or activity of DMR6 protein in the plant. In addition, the invention relates to the use of a DMR6 promotor for providing disease resistant plants.

Abstract: Isolated nucleic acid fragments comprising precursor miRNAs, and artificial miRNAs and their use in down-regulating gene expression are described.

Abstract: A method for synthesizing influenza virus-like particles (VLPs) within a plant or a portion of a plant is provided. The method involves expression of a novel influenza HA protein in plants and its purification The invention is also directed towards a VLP comprising influenza HA protein and plants lipids. The invention is also directed to a nucleic acid encoding improved influenza HA as well as vectors. The VLPs may be used to formulate influenza vaccines, or may be used to enrich existing vaccines.

Abstract: A technique by which the production of plant biomass can be significantly increased is provided. A gene encoding protein phosphatase 2C having 3 consensus sequences comprising the amino acid sequences shown in SEQ ID NOS: 1-3 from the N-terminal side in such order and a gene encoding glutathione-binding plastid-type fructose 1,6-bisphosphate aldolase is introduced, or an expression control region of endogenous genes corresponding to the genes are modified.

Abstract: Methods are described for the identification of genes useful for conferring tolerance in plants to abiotic stress. Transgenic plants and seeds comprising the stress tolerant genes are also described. Methods to monitor the growth rate of the transgenic plants under stressed or non-stressed conditions are also described.

Abstract: A novel Bacillus thuringiensis crystal protein exhibiting insect inhibitory activity is disclosed. Growth of Lygus insects is significantly inhibited by providing the novel crystal protein in Lygus insect diet. Polynucleotides encoding the crystal protein, transgenic plants and microorganisms that contain the polynucleotides, isolated peptides derived from the crystal protein, and antibodies directed against the crystal protein are also provided. Methods of using the crystal protein and polynucleotides encoding the crystal protein to control Hemipteran insects are also disclosed.

Abstract: The invention features compositions comprising in vitro generated beta cells capable of glucose-stimulated insulin secretion, methods of inducing beta cell maturation from embryonic or induced pluripotent stem cell-derived beta-like cells, and methods of using in vitro generated beta cells for the treatment of type 1 diabetes, type 2 diabetes, or a related disorder.

Abstract: The present invention relates to a novel enhancer of protein production in host cells. It discloses a vector for expressing recombinant proteins in these cells, comprising a nucleotide sequence encoding a) a secretion peptidic signal, b) a 6-methylguanine-DNA-methyltransferase enzyme (MGMT, EC 2.1.1.63), a mutant or a catalytic domain thereof, and c) a recombinant protein. Said MGMT enzyme is preferably the so-called SNAP protein.

Abstract: The invention relates to the production of recombinant human fibrinogen (rhFib) in the milk of transgenic mammalian animals. This production and subsequent purification process is generally hampered by the occurrence of so-called ‘clots’ and ‘flakes’ in the milk which, in severe cases, may prevent the cow from being milked at all, resulting in a halt of lactation. These clots and flakes occur because of the expression of the fibrinogen protein, which is a factor that is normally involved in blood clotting. The invention relates to solving this milk clotting problem by treating the (lactating) animals with anticoagulants such as coumarins. A preferred anticoagulant that is used in the methods of the present invention is warfarin.

Abstract: The present invention provides PiggyBac transposase proteins, nucleic acids encoding the same, compositions comprising the same, kits comprising the same, non-human transgenic animals comprising the same, and methods of using the same.

Abstract: Human pluripotent embryonic stem cells produced by somatic cell nuclear transfer as well as methods of making and using said human pluripotent embryonic stem cells are disclosed.

Abstract: Compositions and methods are provided for modifying a genomic locus of interest in a eukaryotic cell, a mammalian cell, a human cell or a non-human mammalian cell using a large targeting vector (LTVEC) comprising various endogenous or exogenous nucleic acid sequences as described herein. Further methods combine the use of the LTVEC with a CRISPR/Cas system. Compositions and methods for generating a genetically modified non-human animal comprising one or more targeted genetic modifications in their germline are also provided.

Abstract: One aspect of the invention relates to industrial bioconversion of the xylose portion of biomass materials into fuels and chemicals. Another aspect of the invention relates to industrial bioconversion of the xylan portion of biomass materials into fuels and chemicals. In one embodiment, the invention is directed to the bacterium Clostridium thermocellum, a highly cellulolytic organism that has much potential as a biocatalyst in a consolidated bioprocess configuration. In some embodiments, the invention is a genetic modification that confers the ability to ferment xylose to C. thermocellum and the strains created with this modification. In some embodiments, the genetic modification is composed of two genes contained in an operon from T. saccharolyticum. The genes express proteins with xylose isomerase (XI) and xylulokinase activites (XK). In other embodiments, the invention relates to a recombinant Clostridium thermocellum host cell capable of fermenting xylan.

Abstract: Provided are microorganisms, e.g., the Saccharomyces yeast, that have been made able to co-ferment xylose sugar-obtained from hydrolyzing plant cellulosic biomass form trees, grasses, straws, etc., with glucose that can be obtained from hydrolyzing either edible feedstocks such as starch, cane sugar, etc. or from hydrolyzing cellulose from various types of non-edible cellulosic biomass. The microorganisms are also capable of expressing an amylase, e.g., glucoamylase, having nonnegligible enzymatic activity, capable of producing glucose from oligo- or polysaccharides obtained by treating soluble starch with ?-amylase. In some embodiments, nucleotidic material is provided comprising genes actively expressing xylose reductase, xylitol dehydrogenase and xylulokinase as well as an active gene expressing glucoamylase. Vectors and other compositions of matter are provided as.

Abstract: The invention provides a recombinant microorganism that has been genetically engineered to contain metabolic pathway for the production of muconic acid from a salicylic acid intermediate. The genetically engineered metabolic pathway comprises both biosynthetic and biodegradative elements.

Abstract: The present disclosure provides acyltransferases useful for synthesizing therapeutically important statin compound.

Abstract: The present disclosure provides methods and systems for amplifying nucleic acid samples. In some aspects, the methods and systems described provided can be useful in conducting multiple nucleic acid amplification reactions in parallel. In some embodiments, methods and systems provided herein can be useful in conducting reverse transcription and DNA amplification in parallel. Moreover, in some aspects, the methods and systems described herein can be useful in analysis of nucleic acid samples. In some embodiments, methods and systems provided herein can be useful for conducting multiple series of primer extension reactions, which can aid in analysis of a nucleic acid sample.

Abstract: An electrochemical test sensor is adapted to measure glucose and correct for the oxygen effect in a fluid sample. The test sensor comprises a base, first and second working electrodes, and a counter electrode. The first working electrode includes glucose oxidase, a mediator and peroxidase. The second working electrode includes glucose oxidase and the mediator. The first working electrode, the second working electrode and the counter electrode are located on the base. In other embodiments, an electrochemical test sensor is adapted to measure cholesterol, lactate, pyruvate or xanthine and correct for the oxygen effect in a fluid sample.

Abstract: Systems and methods for detecting and/or identifying target cells (e.g., bacteria) using engineered transduction particles are described herein. In some embodiments, a method includes mixing a quantity of transduction particles within a sample. The transduction particles are associated with a target cell. The transduction particles are non-replicative, and are engineered to include a nucleic acid molecule formulated to cause the target cell to produce a series of reporter molecules. The sample and the transduction particles are maintained to express the series of the reporter molecules when target cell is present in the sample. A signal associated with a quantity of the reporter molecules is received. In some embodiments, a magnitude of the signal is independent from a quantity of the transduction particle above a predetermined quantity.

Abstract: A magnetic separation system configured to separate with high qualitative and quantitative yield magnetized cells from cell mixtures, comprising at least one electromagnet structured to generate a magnetic field flux about a plurality of separation zones and sufficient to attract a majority of the magnetized cells in the mixture, and a pump to drive the cell mixture at a controlled flow rate through a tube disposed within the zones thereby separating a majority of the magnetized cells from the mixture. The system is particularly useful to retrieve rare cells from a fluid mixture of cells having low abundance of the rare cells relative to the rest of the cells while sustaining viability of the cells.

Abstract: A method for screening a drug for cytochrome P450 (CYP) induction is provided and can include incubating the drug with a microsome-containing biological sample and then quantitating at least one cytochrome P450 isoform. The isoforms can be selected from 2B6, 3A4, 1A2, and 3A5 isoforms. In some embodiments, the method uses liquid chromatography tandem mass spectrometry (LC-MSMS). A quantitated value can be compared to a threshold value and the drug can be determined to exhibit an acceptable CYP induction potential when the quantitated value does not exceed the threshold value. Isolated peptides are also provided.

Abstract: Reagents, assays, methods, kits, devices, and systems for rapid measurement of cholesterol and cholesterol sub-fractions from a blood sample are provided. Total cholesterol, low density lipoprotein cholesterol, and high density lipoprotein cholesterol can be measured in a single assay using kinetic measurements, under conditions in which cholesterol sub-species are converted to a detectable product at distinct rates. The detectable product is measured at different times after assay initiation. A lipase, cholesterol esterase, cholesterol oxidase and a peroxidase may be used together to produce colored product in amounts directly proportional to the quantity of cholesterol converted. Methods for calculating very-low density lipoprotein cholesterol levels by further including triglyceride measurements are disclosed.

Abstract: Systems and methods for monitoring biofilm growth are provided. A method comprises supporting at least one coupon in a water reservoir, wherein the water reservoir feeds water into a tower interior, removing the at least one coupon from the water reservoir, and measuring a level of biofilm growth on the at least one coupon. The level of biofilm growth on the at least one coupon is predictive of a level of biofilm growth within the tower interior. Providing an indicator of predictive biofilm growth may allow measures to be taken to prevent biofilm growth in other sectors or areas of the tower.

Abstract: A system and a method for DNA double-strand break repair in vitro are disclosed. Applications of the disclosed method in multiple areas are also disclosed.

Abstract: The present invention provides an aptamer or pool of aptamers (nucleic acid sequences) that bind(s) to a target molecule on the surface, accessible from the surface or inside of a mammalian sperm cell and a method for producing the aptamers. The method comprises contacting a collection of different nucleic acid molecules with the target molecule under conditions favorable for binding between at least one of the nucleic acid molecules and the target molecule, to form at least one complex comprising the nucleic acid molecule bound to the target molecule, wherein each of the nucleic acid molecules comprises at least one segment of randomized nucleotide sequences. The complexes are then separated from the unbound nucleic acid molecules and unbound target molecules, and the bound nucleic acid molecule is recovered from the separated complex. The aptamers are used to separate sperm cells based upon sperm cell qualities, such as whether the cells contain X chromosomes or Y chromosomes.

Abstract: A method for sequencing a nucleic acid is provided. In certain embodiments the method comprises obtaining a duplex comprising a nucleic acid and a primer, wherein the primer has a nuclease resistant 3? end, combining the duplex with a chain terminator nucleotide and a proof-reading polymerase to produce a reaction in which the polymerase idles on the added chain terminator nucleotide, identifying the chain terminator nucleotide added to the end of the primer; and adding a nuclease-resistant nucleotide to the end of the primer after the polymerase has idled on and removed the added chain terminator nucleotide, thereby producing a duplex comprising the template and an extended primer that has a nuclease resistant 3? end.

Abstract: The present invention provides methods, compositions and kits for detecting duplicate sequencing reads. In some embodiments, the duplicate sequencing reads are removed.

Abstract: The invention relates to devices and methods for nanopore sequencing. The invention provides for using the signals from n-mers to provide sequence information, for example where the system has less than single base resolution. The invention includes arrays of nanopores having incorporated electronic circuits, for example, in CMOS. In some cases, the arrays of nanopores comprise resistive openings for isolating the electronic signals for improved sequencing. Methods for controlling translocation of through the nanopore are disclosed.

Abstract: Disclosed herein are novel assays, systems and kits for selecting a treatment regimen for a subject with depression by identifying at least one nucleic acid polymorphism, e.g., but not limited to, at the MTHFR, MTR, or MTRR locus, and/or determining expression levels of peripheral biomarkers (e.g., SAM, SAH, 4-HNE, and/or hsCRP) in a test sample from a human subject. These biomarkers can be used to determine the effectiveness of treating a depressed subject with a folate-containing compound (alone or as an adjunct to an antidepressant). Additionally, these biomarkers can be used to select an appropriate treatment regimen for subjects with treatment-resistant depression (e.g., resistant to at least one selective serotonin reuptake inhibitor). Methods and compositions for treating at least one symptom (e.g., at least one core symptom) of depression in a subject and/or determining or improving the effectiveness of an antidepressant drug taken by a subject are also provided herein.

Abstract: An ex vivo method of diagnosing or predicting an hereditary spastic paraplegias (HSP) in a subject is provided which comprises detecting a mutation in the KIAA1840 gene or protein (spatacsin), wherein that mutation is indicative of an hereditary spastic paraplegias (HSP).

Abstract: Methods, kits and compositions drawn related to providing controls in diagnostic testing are provided. In one embodiment, a method of verifying proper function of a test for detecting and/or classifying a disease or disorder for which manifestation of a methylated gene is a biomarker is provided. The method includes performing a test for detecting, monitoring, or classifying a disease or disorder, or predisposition thereto, for which manifestation of a methylated gene is a biomarker and verifying proper function of the test by performing (e.g. duplicating or repeating) the test utilizing a control that originates from at least one pregnant female animal. The test includes determining the methylation status of at least one biomarker from a biological sample obtained from an animal subject and verifying proper function of the test by performing the test utilizing a control that originates from at least one pregnant female animal.

Abstract: Described herein are methods, compositions and kits directed to the detection of gene dysregulations such as those arising from gene fusions and/or chromosomal abnormalities, e.g., translocations, insertions, inversions and deletions. Samples containing dysregulated gene(s) of interest may show independent expression patterns for the 5? and 3? regions of the gene. The methods, compositions and kits are useful for detecting mutations that cause the differential expression of a 5? portion of a target gene relative to the 3? region of the target gene.

Abstract: Embodiments of the disclosure relate to isolated nucleic acid sequences, methods of use thereof, and workflows for detection of several Listeria species in a sample, particularly in a food or environmental sample. Embodiments of the disclosure may also be used to detect one or more species or strains of Listeria from each other, for example L. grayi may be detected independently of other Listeria spp. Some embodiments also describe a duplexed assay that can detect L. monocytogenes, L. innocua, L. welshimeri, L. seelgeri, L. marthii (formerly incertae-sedis), L. ivanovii, and L. grayi. Kits for detection of Listeria are also described. In some embodiments, methods and kits of the disclosure may comprise a TAQMAN® assay. In some embodiments, 0.2-2 cfu of Listeria spp. are detected using the compositions, methods and kits after a 24-28 hour enrichment period.

Abstract: A microorganism capable of fixing a carbon oxide and performing fermentation and its preparation method and use are provided, wherein the preparation method comprises: (a) providing a first parental strain which is able to fix a carbon oxide; (b) providing a second parental strain which is able to perform fermentation; (c) preparing a first protoplast and a second protoplast from the first parental strain and the second parental strain, respectively; (d) subjecting the first protoplast and the second protoplast to fuse to provide a fusant; and (e) incubating and selecting the fusant to obtain a target strain. The target strain is useful in the production of an organic compound such as an organic acid and an alcohol, and one embodiment of the target strain is Clostridium tyrobutyricum ITRI02001, deposited at German Collection of Microorganisms and Cell Cultures (Deutsche Sammlung von Mikroorganismen and Zellkulturen GmbH, DSMZ) under the accession number DSM 32077.

Abstract: The invention relates to the increase (improvement) of the effectiveness of antiseptics and/or disinfectants administered in a mixture with hydrolytic or proteolytic enzymes to a mucous membrane, a skin of a mammal or inanimate surfaces in the form of a solution, gel, paste, capsules or other as an agent. The use of the mixture is also stated.

Abstract: A method for quenching a steel pipe by water cooling from an outer surface thereof, where pipe end portions are not subjected to water cooling, and at least part of a main body other than the pipe end portions is subjected to water cooling. A region(s) that is not subjected to direct water cooling over an entire circumference thereof can be along an axial direction at least in part of the main body other than the pipe end portions. The start and stop of water cooling can be intermittent at least in part of the quenching. During the water cooling of the pipe outer surface, an intensified water cooling can be performed in a temperature range in which the pipe outer surface temperature is higher than Ms point. Thereafter, the cooling can be switched to moderate cooling so that the outer surface is cooled down to Ms point or lower.

Abstract: A process for producing DRI from iron ores, utilizing a gas produced from fossil fuels, containing sulfur compounds and BTX, heating said gas in a heater, preferably a regenerator, wherein heat is transferred from a previously-heated solid material to the gas. Flowing the hot gas through a bed of DRI particles, iron oxides or other equivalent material, outside of the reduction reactor, where said material adsorbs sulfur compounds and destroys BTX. The resulting gas, free from sulfur compounds and BTX, is combined with a reducing gas stream from the reduction reactor after H2O and CO2 is at least partially removed for regenerating its reducing potential, with or without undergoing previous cleaning, is used for producing DRI. One inventive embodiment comprises producing DRI at high temperature giving advantageously higher productivity and energy savings when using hot DRI in an electric arc furnace lowering the capital and operational costs of steelmaking.

Abstract: The present invention aims at providing bronze alloy for a musical instrument that has high strength and processability and is provided with excellent acoustic characteristics by addition of Zr. The bronze alloy for a musical instrument according to the present invention has a component composition that contains 18% by mass to 26% by mass of Sn, 0.0005% by mass to 0.25% by mass of Zr, and a remainder consisting of Cu and inevitable impurities. Bronze alloy for a musical instrument having high strength and processability is obtained by setting the component composition as described above. Furthermore, from the frequency analysis result shown in FIG. 6A, in Example 13, higher harmonic components increase and low frequency waves also increase as compared with Comparative Example 2, and it is known that the enhancement of sound qualities such as complexity of beat sounds, profound feeling, and audibility is obtained.